281 related articles for article (PubMed ID: 34526064)
21. Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression.
Yan R; Marshall T; Khullar A; Nagle T; Knowles J; Malkin M; Chubbs B; Swainson J
Ther Adv Psychopharmacol; 2024; 14():20451253241231264. PubMed ID: 38440104
[TBL] [Abstract][Full Text] [Related]
22. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial.
Murphy N; Tamman AJF; Lijffijt M; Amarneh D; Iqbal S; Swann A; Averill LA; O'Brien B; Mathew SJ
Neuropsychopharmacology; 2023 Oct; 48(11):1586-1593. PubMed ID: 37076582
[TBL] [Abstract][Full Text] [Related]
23. Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression.
Pennybaker S; Roach BJ; Fryer SL; Badathala A; Wallace AW; Mathalon DH; Marton TF
Psychopharmacology (Berl); 2021 Nov; 238(11):3229-3237. PubMed ID: 34363507
[TBL] [Abstract][Full Text] [Related]
24. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
[TBL] [Abstract][Full Text] [Related]
25. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
[TBL] [Abstract][Full Text] [Related]
26. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion.
Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
J Affect Disord; 2018 Dec; 241():1-7. PubMed ID: 30081380
[TBL] [Abstract][Full Text] [Related]
27. Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect.
Cui W; Ning Y; Hong W; Wang J; Liu Z; Li MD
Mol Neurobiol; 2019 May; 56(5):3484-3500. PubMed ID: 30140973
[TBL] [Abstract][Full Text] [Related]
28. Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review.
Dai D; Miller C; Valdivia V; Boyle B; Bolton P; Li S; Seiner S; Meisner R
BMC Psychiatry; 2022 Feb; 22(1):140. PubMed ID: 35193541
[TBL] [Abstract][Full Text] [Related]
29. Sex differences in the effects of repeated ketamine infusions on bone markers in patients with unipolar and bipolar depression.
Lan X; Liu H; Wang C; Li W; Zhang F; Hu Z; Chen X; You Z; Ning Y; Zhou Y
Biol Sex Differ; 2024 Jan; 15(1):12. PubMed ID: 38287453
[TBL] [Abstract][Full Text] [Related]
30. Clinical predictors of ketamine response in treatment-resistant major depression.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Guevara S; Machado-Vieira R; Richards EM; Brutsche NE; Nolan NM; Zarate CA
J Clin Psychiatry; 2014 May; 75(5):e417-23. PubMed ID: 24922494
[TBL] [Abstract][Full Text] [Related]
31. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
[TBL] [Abstract][Full Text] [Related]
32. Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression.
Zavaliangos-Petropulu A; McClintock SM; Khalil J; Joshi SH; Taraku B; Al-Sharif NB; Espinoza RT; Narr KL
J Affect Disord; 2023 Jul; 333():161-171. PubMed ID: 37060953
[TBL] [Abstract][Full Text] [Related]
33. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression.
Shiroma PR; Albott CS; Johns B; Thuras P; Wels J; Lim KO
Int J Neuropsychopharmacol; 2014 Nov; 17(11):1805-13. PubMed ID: 24963561
[TBL] [Abstract][Full Text] [Related]
34. Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials.
Chen MH; Wu HJ; Li CT; Lin WC; Tsai SJ; Hong CJ; Tu PC; Bai YM; Mao WC; Su TP
J Psychiatr Res; 2021 Dec; 144():448-454. PubMed ID: 34752941
[TBL] [Abstract][Full Text] [Related]
35. Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals.
Mkrtchian A; Evans JW; Kraus C; Yuan P; Kadriu B; Nugent AC; Roiser JP; Zarate CA
Mol Psychiatry; 2021 Jul; 26(7):3292-3301. PubMed ID: 32929215
[TBL] [Abstract][Full Text] [Related]
36. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
Allen AP; Naughton M; Dowling J; Walsh A; Ismail F; Shorten G; Scott L; McLoughlin DM; Cryan JF; Dinan TG; Clarke G
J Affect Disord; 2015 Nov; 186():306-11. PubMed ID: 26275358
[TBL] [Abstract][Full Text] [Related]
37. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
38. [Ketamine's antidepressant effect: focus on ketamine mechanisms of action].
De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
Encephale; 2014 Feb; 40(1):48-55. PubMed ID: 24434007
[TBL] [Abstract][Full Text] [Related]
39. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
[TBL] [Abstract][Full Text] [Related]
40. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
